Impact of breast cancer on prospective memory functioning assessed by virtual reality and influence of sleep quality and hormonal therapy: PROSOM-K study (original) (raw)
Related papers
Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy
Breast Care, 2016
Introduction: It is generally accepted that estrogens play a protective role in cognitive function. Therefore, it can be expected that subtotal estrogen deprivation following aromatase inhibition will alter cognitive performance. Methods: In a cross-sectional study we investigated 80 postmenopausal women with breast cancer. Memory and spatial cognition were compared across 4 treatment groups: tamoxifen only (TAM, n = 22), aromatase inhibitor only (AI, n = 22), TAM followed by AI (‘SWITCH group', n = 15), and patients with local therapy (LT) only (surgery and radiation, n = 21). Duration of the 2 endocrine monotherapy arms prior to the assessment ranged from 1 to 3 years. The ‘SWITCH group' received 2-3 years TAM followed by at least 1 year and at most 3 years of AI. Memory and spatial cognition were investigated as planned comparisons. Investigations of processing speed, attention, executive function, visuoconstruction and self-perception of memory were exploratory. Results:...
Sleep and Prospective Memory: A Retrospective Study in Different Clinical Populations
International Journal of Environmental Research and Public Health, 2020
Prospective memory (PM) is essential in everyday life because it concerns the ability to remember to perform an intended action in the future. This ability could be influenced by poor sleep quality, the role of which, however, is still being debated. To examine the role of sleep quality in PM in depth, we decided to perform a retrospective naturalistic study examining different clinical populations with a primary sleep disorder or comorbid low sleep quality. If sleep is important for PM function, we could expect poor sleep to affect PM performance tasks both directly and indirectly. We examined a total of 3600 nights, recorded using actigraphy in participants belonging to the following groups: primary insomnia (731 nights); narcolepsy type 1 (1069 nights); attention deficit hyperactivity disorder (152 nights in children and 239 in adults); severe obesity (232 nights); essential hypertension (226 nights); menopause (143 nights); healthy controls (808 nights). In a naturalistic activi...
Anticancer Research
Background/Aim: Upcoming radiotherapy may cause distress and sleep disorders (SDO). This prospective interventional trial investigated SDO during a course of radiotherapy for breast cancer. Patients and Methods: Fifty patients were eligible. The primary endpoint was improvement of SDO after 15 fractions. Additional endpoints included SDO after 5 fractions and at the end of radiotherapy (EOT). Additional characteristics were analysed including use of smartphones/tablets, age, body mass index, performance score, comorbidity score, surgery, distress score, and emotional/ physical/practical problems. Results: After 15 fractions, 38% of patients reported improvement of SDO (p<0.0001). Improvement rates were 22% after 5 fractions (p=0.003) and 39% at EOT (p<0.0001). Moreover, a significant association was observed for lower distress score after 5 fractions. Conclusion: Improvement of SDO occurred more often than expected, most likely due to habituation to radiotherapy. Since SDO did not improve in the majority of patients, timely psychological support should be offered to all patients.
Asia-Pacific Journal of Oncology Nursing, 2022
ObjectiveThis brief study aimed to examine the potential effects of virtual reality (VR)-assisted cognitive rehabilitation intervention on the health outcomes of patients with cancer.MethodsA single group of pre-test and post-test study designs were used. An innovative VR system was developed to assess cancer-related cognitive impairment and provide cognitive rehabilitation. The potential effects of the system were determined by measuring changes in cognitive function (learning and memory, information processing speed, executive function, and verbal fluency) and the severity of depression, anxiety, and insomnia.ResultsNine subjects completed the entire VR intervention and were included in the analysis. The participants’ mean age was 43.3 years (standard deviation, 8.9 years). The VR-based cognitive intervention significantly improved the subjective cognitive measures of perceived cognitive impairment and perceived cognitive ability (P = 0.01 and P < 0.01, respectively). The intervention also improved the objective cognitive measures of verbal learning memory as measured using the Auditory Verbal Learning Test (eg., P < 0.01 for 5-min delay recall), information processing speed as measured using the trail-making test-A (P = 0.02) and executive function as measured using the trail-making test-B (P = 0.03). Only the subtest of delayed recall showed no statistically significant difference after the intervention (P = 0.69). The VR-based psychological intervention significantly reduced the severity of sleep disorders (P < 0.01).ConclusionsThe use of immersive VR was shown to have potential effects on improving cognitive function for patients with cancer. Future studies will require a larger sample size to examine the effects of immersive VR-assisted cognitive rehabilitation on the health outcomes of patients with cancer.
Psicooncologia
Objetivo: El presente artículo resume el apoyo empírico actual para el Entrenamiento de la Adaptación de la Memoria y la Atención (MAAT), un programa de tratamiento cognitivo-conductual que utiliza un enfoque de estrategia compensatoria para el manejo de los efectos cognitivos tardíos de la quimioterapia en los supervivientes del cáncer. Se presenta una descripción del MAAT, además de otros enfoques de tratamiento. Resultados: Es necesario ampliar los métodos actuales de evaluación de las mejorías del tratamiento en los supervivientes de cáncer con problemas cognitivos que han completado programas como el MAAT. En este sentido, se propone una tabla de medidas de resultado informadas (PRO) por el paciente que puede ser más adecuada para la investigación de resultados futuros. Conclusiones: Identificar medidas de de resultado que evalúen con precisión los objetivos clínicos del MAAT y otros tratamientos conductuales es de vital importancia, ya que algunas variables (ej., calidad de vida, estrés de rol), no son detectados por pruebas neuropsicológicas de modo aislado. La tabla de PRO presentada en este artículo tiene el propósito de ayudar a los futuros investigadores a identificar las medidas que pueden reflejar la mejoría en calidad de vida en respuesta a tratamientos como el MAAT.
Supportive Care in Cancer
Purpose To examine long-term cognitive effects of chemotherapy and identify predictors among women with breast cancer (WBC). Patients and methods Sixty-nine WBC scheduled to receive chemotherapy, and 64 matched-controls with no cancer, participated. Objective and subjective cognition, total sleep time, nap time, circadian activity rhythms (CAR), sleep quality, fatigue, and depression were measured pre-chemotherapy (Baseline), end of cycle 4 (Cycle-4), and one-year post-chemotherapy (1-Year). Results WBC showed no change in objective cognitive measures from Baseline to Cycle-4 but significantly improved from both time points to 1-Year. Matched-controls showed an increase in test performance at all time points. WBC had significantly higher self-reported cognitive dysfunction at Cycle-4 and 1-Year compared to baseline and compared to matched-controls. Worse neuropsychological functioning was predicted by less robust CARs (i.e., inconsistent 24 h pattern), worse sleep quality, longer na...
in Vivo, 2021
Background/Aim: The anticipation of radiotherapy can cause distress and sleep disorders, which may be aggravated by the COVID-19 pandemic. This study investigated sleep disorders in a large cohort of patients with breast cancer before and during the pandemic. Patients and Methods: Twenty-three characteristics were retrospectively analyzed for associations with pre-radiotherapy sleep disorders in 338 patients. Moreover, 163 patients presenting before and 175 patients presenting during the COVID-19 pandemic were compared for sleep disorders. Results: Sleep disorders were significantly associated with age ≤60 years (p=0.006); high distress score (p<0.0001); more emotional (p<0.0001), physical (p<0.0001) or practical (p<0.0001) problems; psycho-oncological need (p<0.0001); invasive cancer (p=0.003); chemotherapy (p<0.001); and hormonal therapy (p=0.006). Sleep disorders were similarly common in both groups (prior to vs. during the pandemic: 40% vs. 45%, p=0.38). Conclusion: Although additional significant risk factors for sleep disorders were identified, the COVID-19 pandemic appeared to have no significant impact on sleep disorders in patients scheduled for irradiation of breast cancer.
European Journal of Cancer Care, 2020
Breast cancer is the most diagnosed type of cancer among women, and its different types of available treatments may negatively affect functioning, physical capacity and quality of life of women diagnosed with this cancer (Carvalho et al., 2013; Ferlay et al., 2015; Vitale et al., 2015). Among the events commonly reported by patients during treatment and throughout disease-free survival are decreased functioning, pain, low aerobic capacity, anxiety, mood disorders, depressive symptoms, fatigue and sleep disturbances, which may result in future health problems (Ancoli-Israel et al., 2014; Peerawong et al., 2016). Sleep is a transient, reversible and multifaceted state necessary for body recovery and balance. Many structures of the central nervous system are involved in multiple sleep-related physiological and behavioural mechanisms. (Luyster et al., 2012; Vitale et al., 2015). Consequences of poor sleep quality (PSQ) involve impairments to both mental and organic functions (Mercier et al., 2017). Previous studies conducted on breast cancer survivors (BCS) found that 97.4% had more than one sleep disorder, and the most common were chronic insomnia (98%) and circadian rhythm disorders (84%) (Otte et al., 2016). The evidence shows that cancer-related treatment improve the number of patients who reported poor sleep (Fakih et al.,